Search alternatives:
linear decrease » linear increase (Expand Search)
larger decrease » marked decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
linear decrease » linear increase (Expand Search)
larger decrease » marked decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
6401
Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi...
Published 2025“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
-
6402
Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi...
Published 2025“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
-
6403
Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi...
Published 2025“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
-
6404
Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi...
Published 2025“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
-
6405
-
6406
-
6407
-
6408
-
6409
-
6410
-
6411
-
6412
-
6413
-
6414
Table 1_Age-related lung structure changes by quantitative assessment: a cross-sectional study in a Chinese male cohort.docx
Published 2025“…</p>Conclusion<p>Lung aging is not a linear process, and the lung structural alterations in the upper and lower lobes exhibit significant heterogeneity.…”
-
6415
VB2 cell fate analysis of <i>hlh-17</i>, <i>hlh-31</i>, and <i>hlh-32</i> mutant animals.
Published 2025“…<p>(<b>A</b>) In <i>hlh-17/31/32</i><sup>null</sup> mutants, VB2 adopts a VB1-like NeuroPAL <i>(otIs669)</i> coloring. …”
-
6416
Data Sheet 1_Metabolic adaptation fluctuates with different prediction equations: a secondary analysis based on a weight-loss clinical trial.docx
Published 2025“…Both Katch-McArdle-determined RMR and BIA-determined RMR presented a significant decrease between baseline and the end of the intervention (week 16). …”
-
6417
Kaplan-Meier plot.
Published 2024“…</p><p>Findings</p><p>All four districts showed a decrease in case notification rates since 2015, with the steepest decline in the intervention districts. …”
-
6418
Characteristics of the study sample.
Published 2024“…</p><p>Findings</p><p>All four districts showed a decrease in case notification rates since 2015, with the steepest decline in the intervention districts. …”
-
6419
Multivariate associations with incident leprosy.
Published 2024“…</p><p>Findings</p><p>All four districts showed a decrease in case notification rates since 2015, with the steepest decline in the intervention districts. …”
-
6420
Univariate associations with incident leprosy.
Published 2024“…</p><p>Findings</p><p>All four districts showed a decrease in case notification rates since 2015, with the steepest decline in the intervention districts. …”